Column List | SMC Laboratories Inc.

2025.06.06

A Preclinical Package to Maximize the Value of Your MASH Candidate

Featured in Frontiers in Immunology | SMC Laboratories Featured in Frontiers in Immunology:A Preclinical Package to Maximize the Value of Your MASH Candidate We are excited to share that a study for which we conducted the preclinical efficacy pharmacology has been published in the journal, Frontiers in Immunology. The paper features the novel MASH drug…

2025.05.30

[New model]Rat CCl4-induced Acute Liver Injury Model

New In Vivo Model Rat CCl4-induced Acute Liver Injury Model Accelerate the efficacy evaluation of your hepatoprotective and anti-inflammatory drugs with our reliable and precise new model. Facing Challenges in Liver Disease Drug Development? Need to evaluate hepatoprotective effects with a reliable in vivo model? Looking to quickly narrow down candidate compounds and shorten your…

2025.05.23

Visit SMC at the 61st Annual Meeting of the Japan Society of Hepatology

Today, we are excited to announce that we will be attending the “61st Annual Meeting of the Japanese Society of Hepatology” which will be held on June 5th, Thursday and June 6th, Friday, at New Otani Hotel (Tokyo). We will be happy to introduce our disease mouse models of inflammation and fibrosis in various organs,…

2025.05.16

Proposals to evaluate single test substance with multiple models

Today, we’d like to make suggestions on how to maximize the value of your preclinical data you have obtained with us. 2 strategic approaches to expand the potential of drug development We propose the following approaches for further expansion of your current drug development. Proposal 1: Indication expansion strategy: Expanding disease area In recent years,…

2025.05.09

Unlock the Full Potential of Your Compounds: A Proposal for Tailored Evaluation Solutions

In today’s increasingly competitive landscape of new drug development, where a more individualized approach is crucial, are you encountering challenges such as: – “Existing models and evaluation systems fall short of fully assessing the unique characteristics of our company’s compounds.” – “Commonly used models lack reproducibility, leading to wasted time and resources.” – “We want…

2025.05.02

Addressing Unmet Needs with Tailored Non-Clinical Solutions

Idiopathic Pulmonary Fibrosis (IPF) remains a high-priority therapeutic area, where current standard-of-care (SOC) treatments such as Nintedanib and Pirfenidone help slow disease progression, but do not halt it entirely. Despite treatment, mortality remains high, and there is limited improvement in quality of life and overall survival. The urgent need for safer and more effective therapies…

2025.04.25

Liraglutide Evaluation in the CDAHFD Model

We would like to share with you our latest data obtained using the CDAHFD (Choline-Deficient, High-Fat Diet) mouse model, which rapidly reproduces key features of MASH, including steatosis, inflammation, and fibrosis. In this study, we evaluated the GLP-1 receptor agonist Liraglutide, and observed a clear anti-fibrotic effect in this model. Overview of the CDAHFD Model Induced by a…

2025.04.18

Obese MASH model

We will introduce the obese MASH model in this article. Existing MASH (metabolic dysfunction-associated steatohepatitis) models have different characteristics, such as obese/non-obese type, presence/absence of dyslipidemia, and differences regarding the capability to progression to HCC. Since MASH is a complex disease with diverse ways of pathogenesis, it is important to evaluate your test substance in multiple…

2025.04.11

Choosing the Right PSC Model for Your Research

In this article, we will introduce the key points for selecting a model that will lead to the success of your PSC research. Ideal features of a PSC model: ・Duct injury (intra- and extrahepatic) ・Ductular reaction ・Onion-like periductal fibrosis ・Portal inflammation ・Association with IBD ▼ ▼ ▼ …

2025.04.04

【New Publication】Suppressing MASH Progression Using the STAM Mouse Model

A recent study using the STAM™ mouse model demonstrates clear efficacy in MASH progression inhibition – this could support your preclinical strategy. ▶ Publication: Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH In this paper, the authors highlight the effect of 2-HOBA, a scavenger of reactive dicarbonyl electrophiles (DE), in improving MASH by reducing…